Scientists Make Bone Marrow-on-a-chip
The latest organ-on-a-chip from Harvard’s Wyss Institute for Biologically Inspired Engineering reproduces the structure, functions and cellular make-up of bone marrow, a complex tissue that until now could only be studied intact in living animals, Institute researchers report in Nature Methods. The device, dubbed “bone marrow-on-a-chip,” gives scientists a much-needed new tool to test the effects of new drugs and toxic agents on whole bone marrow.
Specifically, the device could be used to develop safe and effective strategies to prevent or treat radiation’s lethal effects on bone marrow without resorting to animal testing, a challenge that is being pursued at the Institute with funding support from the U.S. Food & Drug Administration (FDA). In an initial test, the engineered bone marrow, like human marrow, withered in response to radiation unless a drug known to prevent radiation poisoning was present.
Read more: http://www.laboratoryequipment.com/news/2014/05/scientists-make-bone-marrow-chip
Treatment for Heart Disease May Be Found in Bones
Taking stem cells from a patient’s bone marrow and injecting them into damaged heart tissue may become an effective way to treat heart disease, suggests a new study. Researchers reviewed data from the clinical trials that have been conducted so far of these novel therapies.
“This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, it is generated from small studies and it is difficult to come to any concrete conclusions until larger clinical trials that look at longer-term effects are carried out,” says Enca Martin-Rendon of the Univ. of Oxford and a member of the Cochrane Heart Review Group that carried out the study.
Read more: http://www.laboratoryequipment.com/news/2014/04/treatment-heart-disease-may-be-found-bones
Drug Fights Cancer Reservoirs in Bone Marrow
Cancer drugs that recruit antibodies from the body’s own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return.
A new study from MIT reveals a way to combat these recurrent tumors with a drug that makes them more vulnerable to the antibody treatment. This drug, known as cyclophosphamide, is already approved by the Food and Drug Administration to treat some cancers.
Read more: http://www.laboratoryequipment.com/news/2014/01/drug-fights-cancer-reservoirs-bone-marrow
Bone Marrow Recipient Cured of Peanut Allergy
Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma, and Immunology’s (ACAAI) Annual Scientific Meeting, a 10-year-old boy no longer had a peanut allergy after undergoing a bone marrow transplant.
"It has been reported that bone marrow and liver transplants can transfer peanut allergy from donor to recipient," says allergist Yong Luo, ACAAI member and lead study author. "But our research found a rare case in which a transplant seems to have cured the recipient of their allergy."
Read more: http://www.laboratoryequipment.com/news/2013/11/bone-marrow-recipient-cured-peanut-allergy
Men Show No Sign of HIV After Marrow Transplant
Two HIV-positive patients in the U.S. who underwent bone marrow transplants for cancer have stopped anti-retroviral therapy and still show no detectable sign of the HIV virus, researchers said today.
The Harvard Univ. researchers stressed it was too early to say the men have been cured, but said it was an encouraging sign that the virus hasn’t rebounded in their blood months after drug treatment ended.
Read more: http://www.laboratoryequipment.com/news/2013/07/men-show-no-sign-hiv-after-marrow-transplant
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the Univ. of Michigan Comprehensive Cancer Center.
The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 21 percent of patients developing graft-vs.-host disease compared to 42 percent of patients who typically develop this condition with standard medications alone.
Read more: http://www.laboratoryequipment.com/news/2012/12/drug-cuts-deadly-transplant-risk-half
Bone Marrow to Fight Lou Gehrig’s Disease
The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson’s and ALS, is the holy grail of brain research. A technology developed at Tel Aviv Univ. does just that, and it’s now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Read more: http://www.laboratoryequipment.com/news-Bone-Marrow-to-Fight-Lou-Gehrigs-Disease-092111.aspx